Action SNDX SYNDAX PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Syndax Pharmaceuticals, Inc.

Actions

SNDX

US87164F1057

Temps réel estimé Cboe BZX
Autres places de cotation
 20:54:37 16/05/2024 		Varia. 5j. Varia. 1 janv.
20,86 USD -4,92 % Graphique intraday de Syndax Pharmaceuticals, Inc. -5,28 % -3,70 %
15/05 Syndax Pharmaceuticals, Inc. annonce des changements au sein de son conseil d'administration CI
08/05 La perte nette de Syndax Pharmaceuticals au premier trimestre s'aggrave MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
Syndax Pharmaceuticals, Inc. Announces Board Changes
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals Q1 Net Loss Widens
Syndax Pharmaceuticals : First Quarter 2024 Conference Call
Syndax: Q1 Earnings Snapshot
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
Syndax Says Revumenib NDA Granted FDA Priority Review
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Sector Update: Health Care Stocks Rise Monday Afternoon
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SNDX
  4. Actualités Syndax Pharmaceuticals, Inc.
  5. Autres langues